|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Liver Cancer
|
NCI
|
4R37CA053394-17
|
|
Mechanism of action of the v-erb A oncogene of AEV.
|
PRIVALSKY, MARTIN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$300,645
|
|
Liver Cancer
|
NCI
|
5R01CA082723-09
|
|
K Vitamins- A New Class of Liver Cell Growth Inhibitors
|
CARR, BRIAN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$263,832
|
|
Liver Cancer
|
NIAID
|
2R01AI020001-25
|
|
Pathogenesis of Liver Disease in Hepatitis
|
CHISARI, FRANCIS
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$685,357
|
|
Liver Cancer
|
NIEHS
|
5F32ES014777-02
|
|
Role of estrogen receptor beta in cancer prevention by dietary indole-3-carbinol
|
BENNINGHOFF, ABBY
|
OREGON STATE UNIVERSITY
|
OR
|
$24,398
|
|
Liver Cancer
|
NIAID
|
5R01AI064844-03
|
|
Role of Hepatitis B virus X protein in HBV replication.
|
BOUCHARD, MICHAEL
|
DREXEL UNIVERSITY
|
PA
|
$315,019
|
|
Liver Cancer
|
NIEHS
|
5R01ES007800-12
|
|
Ah Receptor Anatomy: Implications for Dioxin Toxicity
|
ELFERINK, CORNELIS
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$330,706
|
|
Liver Cancer
|
NCI
|
5R01CA124648-02
|
|
An integrative approach to cancer gene discovery in hepatocellular carcinoma
|
POWERS, SCOTT
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$419,084
|
|
Liver Cancer
|
NIDDK
|
5R01DK048252-15
|
|
Pathophysiology of Distal Tyrosine Pathway Disorders
|
GROMPE, MARKUS
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$308,500
|
|
Liver Cancer
|
NCI
|
5R01CA102325-04
|
|
cPLA2, COX-2 and PPAR-gamma in Cholangiocarcinoma
|
WU, TONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$224,802
|
|
Liver Cancer
|
NCI
|
5F32CA111040-03
|
|
Modulation of Hepatic N-Myristoyltransferases by Dioxins
|
WORMKE, MARK
|
NATL RESEARCH CTR/ENVIRONMENT & HEALTH
|
GERM
|
$45,048
|
|
Liver Cancer
|
NCI
|
5R01CA106280-04
|
|
Prostaglandin Signaling Pathway in Liver Cancer
|
WU, TONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$224,802
|
|
Liver Cancer
|
NIGMS
|
5R01GM031555-25
|
|
Factors in the Prevention of Toxic Liver Injury
|
BOYER, THOMAS
|
UNIVERSITY OF ARIZONA
|
AZ
|
$343,622
|
|
Liver Cancer
|
NICHD
|
5R01HD035831-09
|
|
Nutritional Regulation of Fetal Liver Development
|
GRUPPUSO, PHILIP
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$225,382
|
|
Liver Cancer
|
NIDDK
|
5R01DK062277-05
|
|
Role of Wnt/Beta-Catenin Signaling in Liver Development
|
MONGA, SATDARSHAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$218,911
|
|
Liver Cancer
|
NCI
|
5R01CA039416-23
|
|
Molecular Mechanisms of Chemoprevention: Dithiolethiones
|
KENSLER, THOMAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$502,144
|
|
Liver Cancer
|
NCI
|
5R01CA083650-09
|
|
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER
|
SIRICA, ALPHONSE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$302,232
|
|
Liver Cancer
|
NIAID
|
5R01AI030070-16
|
|
Regulation of Hepatitis B Virus Transcription
|
MCLACHLAN, ALAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$512,408
|
|
Liver Cancer
|
NCI
|
5R01CA100908-04
|
|
Role of Kupffer Cell in Hepatic Carcinogenesis
|
KLAUNIG, JAMES
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$226,529
|
|
Liver Cancer
|
NCI
|
5R01CA076183-06
|
|
Targeting diffuse liver metastases with Herpes virus
|
TANABE, KENNETH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$375,113
|
|
Liver Cancer
|
NCI
|
5R01CA114403-03
|
|
Biliary oxysterols and cholangiocarcinoma
|
KUVER, RAHUL
|
SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
|
WA
|
$212,356
|
|
Liver Cancer
|
NCI
|
5R37CA023226-37
|
|
GENE EXPRESSION IN REGENERATING AND NEOPLASTIC LIVERS
|
FAUSTO, NELSON
|
UNIVERSITY OF WASHINGTON
|
WA
|
$378,690
|
|
Liver Cancer
|
NCI
|
5R01CA111355-04
|
|
Low birth weight & other risk factors for hepatoblastoma
|
SPECTOR, LOGAN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$492,347
|
|
Liver Cancer
|
NIEHS
|
1R01ES016313-01
|
|
The Environment as a Variable to Calibrate Mouse Models of Human Disease
|
ESSIGMANN, JOHN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$544,391
|
|
Liver Cancer
|
NCI
|
5R01CA115625-02
|
|
Proteomic Analysis of Serum in Liver Cancer
|
GOLDMAN, RADOSLAV
|
GEORGETOWN UNIVERSITY
|
DC
|
$340,569
|
|
Liver Cancer
|
NIAID
|
1R21AI076706-01
|
|
Impact of NK Cell Immune Pressures on HCV Evolution and Viral Fitness
|
ALTFELD, MARCUS
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$263,250
|
|
Liver Cancer
|
NIDDK
|
2R01DK063947-06
|
|
Organelle Dysfunction and Apoptosis in Liver Epithelia
|
GORES, GREGORY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$288,979
|
|
Liver Cancer
|
NIDDK
|
5R03DK077707-02
|
|
Early Detection and Prognosis of Patients with Hepatocellular Carcinoma
|
MARRERO, JORGE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$74,480
|
|
Liver Cancer
|
NCI
|
5R01CA109733-04
|
|
Molecular Target(s) for Interruption of HBV Infection
|
LI, JISU
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$214,052
|
|
Liver Cancer
|
NCI
|
5R37CA081301-10
|
|
Metabolism of Carcinogenic Tobacco-Specific Nitrosamines
|
HECHT, STEPHEN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$477,962
|
|
Liver Cancer
|
NCI
|
5R01CA121171-03
|
|
Molecular mediators of metastasis in hepatocellular carcinoma
|
LEWIS, BRIAN
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$280,074
|
|
Liver Cancer
|
NIAID
|
5R21AI067455-02
|
|
Resolution of Acute Hepatitis B Virus Infections in Chimpanzees
|
LANFORD, ROBERT
|
SOUTHWEST FOUNDATION FOR BIOMEDICAL RES
|
TX
|
$222,579
|
|
Liver Cancer
|
NIAID
|
5R01AI069285-02
|
|
Role of TLR3 Signaling in Control of HCV
|
LI, KUI
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$126,887
|
|
Liver Cancer
|
NCI
|
5R03CA119313-02
|
|
Novel Machine Learning Methods for Analysis of MALDI-TOF Mass Spectrometry Data
|
RESSOM, HABTOM
|
GEORGETOWN UNIVERSITY
|
DC
|
$77,600
|
|
Liver Cancer
|
NCI
|
5R01CA103958-05
|
|
HGF and Signaling Pathways in Hepatic Tissue Assembly
|
MICHALOPOULOS, GEORGE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$282,995
|
|
Liver Cancer
|
NIDDK
|
5R01DK066939-05
|
|
Modulation of HCV Gene Expression
|
BRANCH, ANDREA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$370,132
|
|
Liver Cancer
|
NCI
|
5R01CA102575-04
|
|
Mechanism of gallbladder tumorigenesis in BK5.erbB2 mice
|
KIGUCHI, KAORU
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$224,720
|
|
Liver Cancer
|
NCI
|
1R01CA126807-01A1
|
|
HCV genetic variation and hepatocellular carcinoma
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$274,523
|
|
Liver Cancer
|
NCI
|
5R37CA090426-08
|
|
Metabolism of Carcinogens and Drugs by Human P450s
|
GUENGERICH, F
|
VANDERBILT UNIVERSITY
|
TN
|
$353,556
|
|
Liver Cancer
|
NIDDK
|
2R01DK033765-25
|
|
Cytochrome P450-Endogenous Substrate Metabolism
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
MA
|
$445,250
|
|
Liver Cancer
|
NIDDK
|
5R01DK056669-07
|
|
Transcriptional control in hepatocyte proliferation
|
GREENBAUM, LINDA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$316,418
|
|
Liver Cancer
|
NCI
|
5R01CA100882-05
|
|
Molecular Pathogenesis of Hepatocellular Carcinoma
|
ROBERTS, LEWIS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$258,035
|
|
Liver Cancer
|
NIDDK
|
1R01DK073897-01A2
|
|
Iron-Induced Changes in Liver That Predispose to Malignancy
|
ISOM, HARRIET
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$245,493
|
|
Liver Cancer
|
NCI
|
2R01CA086978-06A1
|
|
Molecular mechanism of diet induced carcinogenesis
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
OH
|
$302,115
|
|
Liver Cancer
|
NCI
|
5U01CA120475-02
|
|
The Role of mTOR Signaling in Hepatocellular Carcinogenesis
|
KOZMA, SARA
|
UNIVERSITY OF CINCINNATI
|
OH
|
$296,400
|
|
Liver Cancer
|
NIDDK
|
5R01DK045334-15
|
|
Regulation of Hepatic Glutathione Synthesis
|
LU, SHELLY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$266,573
|
|
Liver Cancer
|
NIDDK
|
5R01DK051719-12
|
|
REGULATION OF METHIONINE ADENOSYLTRANSFERASE IN LIVER
|
LU, SHELLY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$317,971
|
|
Liver Cancer
|
NIDDK
|
5R01DK069558-03
|
|
Purinergic Regulation of hepatocyte proliferation
|
THEVANANTHER, SUNDARARAJAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$263,351
|
|
Liver Cancer
|
NIAID
|
5R01AI018641-26
|
|
Hepadnavirus Infections and Liver Cancer
|
MASON, WILLIAM
|
INSTITUTE FOR CANCER RESEARCH
|
PA
|
$562,151
|
|
Liver Cancer
|
NIDDK
|
5F32DK079860-02
|
|
Characterization of the Assembly and Egress Pathway of Hepatitis C Virus
|
SHOHDY, NADIM
|
ROCKEFELLER UNIVERSITY
|
NY
|
$49,646
|
|
Liver Cancer
|
NCI
|
1R21CA129676-01A1
|
|
Serum Biomarkers of Hepatic Response to Cancer Chemopreventive Intervention
|
GROOPMAN, JOHN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$214,020
|
|
Liver Cancer
|
NCI
|
1K25CA127524-01A1
|
|
Biomarker Discovery for Hepatitis C Progression using Machine Learning Techniques
|
SPRATT, HEIDI
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$126,357
|
|
Liver Cancer
|
NCI
|
1R21CA127046-01A1
|
|
Analysis of the Cytokine-Immunological Model of a Cancer-Related Symptom Cluster
|
STEEL, JENNIFER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$204,525
|
|
Liver Cancer
|
NIDDK
|
1R01DK078686-01A1
|
|
Genetic and epigenetic regulation of Hepatitis B contributes to liver cancer
|
TORBENSON, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$348,500
|
|
Liver Cancer
|
NCI
|
5R01CA118165-02
|
|
Role of inflammation in tumor promotion and progression
|
KARIN, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$450,258
|
|
Liver Cancer
|
NIDDK
|
5R01DK059427-08
|
|
Mechanisms of Carcinogenesis in Biliary Epithelia
|
GORES, GREGORY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$273,204
|
|
Liver Cancer
|
NCI
|
5R21CA122523-02
|
|
Role of metallothioneins in hepatocellular carcinoma
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
OH
|
$150,000
|
|
Liver Cancer
|
NCI
|
5R01CA112053-04
|
|
Mechanisms of the HBX-interacting protein (HBXIP)
|
REED, JOHN
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$357,678
|
|
Liver Cancer
|
NIDDK
|
5R01DK069859-03
|
|
Genes Related to HCC Progression in LD and DD Transplant
|
FISHER, ROBERT
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$482,550
|
|
Liver Cancer
|
NIDDK
|
5K23DK064909-05
|
|
Complications of Cirrhosis in American Patients
|
MARRERO, JORGE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$132,300
|
|
Liver Cancer
|
NIAID
|
5R01AI050798-05
|
|
Functional analysis of hepatitis C virus glycoproteins
|
MCKEATING, JANE
|
UNIVERSITY OF BIRMINGHAM
|
UK
|
$200,490
|
|
Liver Cancer
|
NCI
|
5R01CA055578-13
|
|
Role of PreS2 Mutants in Pathogenesis of Chronic Hepatitis B
|
YEN, TIEN-SZE
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$245,449
|
|
Liver Cancer
|
NCI
|
5R21CA124493-02
|
|
Role of thyroid hormone receptor mutants in hepatocellular carcinoma
|
PRIVALSKY, MARTIN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$178,486
|
|
Liver Cancer
|
NCI
|
5R01CA042715-22
|
|
Cellular Origins of Liver Cancer
|
HIXSON, DOUGLAS
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$288,011
|
|
Liver Cancer
|
NIAID
|
5R01AI057504-04
|
|
Regulatory mechanisms of HBV X gene Transcription
|
TAKADA, SHINAKO
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$316,025
|
|
Liver Cancer
|
NCI
|
2R42CA121506-02
|
|
HCC diagnostics defined by fucosylated serum biomarkers
|
MEHTA, ANAND
|
IMMUNOTOPE, INC.
|
PA
|
$564,986
|
|
Liver Cancer
|
NICHD
|
5R01HD024455-19
|
|
Regulation of Fetal Hepatic Growth
|
GRUPPUSO, PHILIP
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$341,180
|
|
Liver Cancer
|
NCI
|
1R41CA132397-01
|
|
Small Molecule Inhibitors of HBV/HCV Induced Liver Diseases
|
DHEER, SURENDRA
|
SONITU PHARMACEUTICALS, LLC
|
PA
|
$168,000
|
|
Liver Cancer
|
NIDDK
|
2R44DK074205-02
|
|
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
|
SVETLOV, STANISLAV
|
BANYAN BIOMARKERS, INC.
|
FL
|
$422,483
|
|
Liver Cancer
|
NCI
|
5R01CA037232-24
|
|
HEPADNAVIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA
|
ROGLER, CHARLES
|
YESHIVA UNIVERSITY
|
NY
|
$483,550
|
|
Liver Cancer
|
NIAID
|
1R43AI074214-01A1
|
|
An RNAi Trojan Horse for treatment of hepatitis C.
|
JOHNSTON, BRIAN
|
SOMAGENICS, INC.
|
CA
|
$295,743
|
|
Liver Cancer
|
NCI
|
1F32CA132312-01
|
|
Identification and Characterization of Liver Cancer Stem Cells
|
BELLOVIN, DAVID
|
STANFORD UNIVERSITY
|
CA
|
$49,646
|
|
Liver Cancer
|
NIDCR
|
5R01DE013158-08
|
|
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
|
LAZARUS, PHILIP
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$483,110
|
|
Liver Cancer
|
NCI
|
5R21CA121051-02
|
|
MR Spectroscopy to Evaluate Liver Repopulation by Transplanted Hepatocytes
|
GUHA, CHANDAN
|
YESHIVA UNIVERSITY
|
NY
|
$160,708
|
|
Liver Cancer
|
NCI
|
5K01CA118722-02
|
|
Mechanism of nitric oxide inhibition of pericyte recruitment in liver tumors
|
KANG-DECKER, NINGLING
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$130,985
|
|
Liver Cancer
|
NCI
|
5R01CA124488-02
|
|
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
|
RAYCHAUDHURI, PRADIP
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$286,458
|
|
Liver Cancer
|
NCI
|
5R01CA067529-14
|
|
Helicobacter induced hepatitis and tumorigenesis
|
FOX, JAMES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$341,346
|
|
Liver Cancer
|
NCI
|
5R01CA116380-03
|
|
Realtime 3D MRI Technologies for Therapy and Diagnosis
|
BLOCK, WALTER
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$248,641
|
|
Liver Cancer
|
NCI
|
5R21CA122317-02
|
|
Development of Glypican-3 as a biomarker for hepatocellular carcinoma
|
SO, SAMUEL
|
STANFORD UNIVERSITY
|
CA
|
$146,400
|
|
Liver Cancer
|
NCI
|
5R01CA085888-09
|
|
Malignant Complications of Chronic HCV
|
LOFFREDO, CHRISTOPHER
|
GEORGETOWN UNIVERSITY
|
DC
|
$297,351
|
|
Liver Cancer
|
NCI
|
5R01CA080118-10
|
|
Cancer-Related Glycolytic Gene:Regulation and Targeting
|
PEDERSEN, PETER
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$232,542
|
|
Liver Cancer
|
NCI
|
5R01CA113447-03
|
|
DNA Repair of Endogenous Lesions in Carcinogenesis
|
ROY, RABINDRA
|
GEORGETOWN UNIVERSITY
|
DC
|
$290,517
|
|
Liver Cancer
|
NCI
|
5R03CA127415-02
|
|
Regulation of androgen metabolism by the nuclear receptor CAR
|
HUANG, WENDONG
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$84,500
|
|
Liver Cancer
|
NCI
|
5R01CA114093-04
|
|
Liver Cancer Ablation Guidance BY ARFI Imaging
|
TRAHEY, GREGG
|
DUKE UNIVERSITY
|
NC
|
$288,390
|
|
Liver Cancer
|
NCI
|
5R21CA121553-02
|
|
Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
|
JARNAGIN, WILLIAM
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$312,246
|
|
Liver Cancer
|
NIDDK
|
5K24DK078154-02
|
|
Epidemiology and Outcomes of Digestive and Liver Diseases: A Mentoring Program
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$149,057
|
|
Liver Cancer
|
NIAID
|
5R01AI049574-08
|
|
GBV-B: A Small Primate Model for Hepatitis C Infection
|
LANFORD, ROBERT
|
SOUTHWEST FOUNDATION FOR BIOMEDICAL RES
|
TX
|
$311,605
|
|
Liver Cancer
|
NCI
|
5R01CA122434-03
|
|
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer
|
ZHOU, XIAO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$293,000
|
|
Liver Cancer
|
NIDDK
|
5R03DK076583-02
|
|
Notch Signaling and Cell Fate in Embryonic and Adult Liver
|
STANGER, BEN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$77,175
|
|
Liver Cancer
|
NCI
|
5F32CA128338-02
|
|
Tissue and Tumor Specific Glycosylation of Proteins
|
WEST, MATTHEW
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$49,646
|
|
Liver Cancer
|
NIDDK
|
5R01DK053224-09
|
|
CXC chemokines and liver regeneration
|
COLLETTI, LISA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$310,489
|
|
Liver Cancer
|
NCI
|
5R01CA111427-05
|
|
Early antibody markers of HCC
|
FEITELSON, MARK
|
TEMPLE UNIVERSITY
|
PA
|
$276,457
|
|
Liver Cancer
|
NCI
|
5R01CA085702-08
|
|
Carcinogenic Cyclic Nitrosamine DNA Adducts
|
HECHT, STEPHEN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$320,088
|
|
Liver Cancer
|
NCI
|
5R01CA109574-04
|
|
RNAi-Based Therapy of Hepatocellular Carcinoma
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$224,720
|
|
Liver Cancer
|
NCI
|
5K01CA107092-05
|
|
Hepatocellular carcinoma: targeting HCV replication
|
LINDENBACH, BRETT
|
YALE UNIVERSITY
|
CT
|
$162,378
|
|
Liver Cancer
|
NCI
|
5R37CA035711-25
|
|
Pathogenesis, Immunodiagnosis and Therapy of HCC
|
WANDS, JACK
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$320,011
|
|
Liver Cancer
|
NCI
|
5R01CA111456-04
|
|
The impact of growth modulation of liver carcinogenesis
|
YIN, XIAO-MING
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$272,640
|
|
Liver Cancer
|
NCI
|
5R21CA128391-02
|
|
Randomized trial of doxorubicin beads for arterial embolization of hepatocellular
|
BROWN, KAREN
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$187,000
|
|
Liver Cancer
|
NCI
|
5R01CA100830-06
|
|
Oncolytic VSV for Hepatocellular Carcinoma
|
WOO, SAVIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$338,076
|
|
Liver Cancer
|
NIDDK
|
5K08DK071940-04
|
|
wnt Signaling in Liver Development and Disease
|
GOESSLING, WOLFRAM
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$134,730
|
|
Liver Cancer
|
NCI
|
1R25CA129042-01A1
|
|
Asian American Liver Cancer Education Program in Maryland
|
JUON, HEE-SOON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$276,609
|
|
Liver Cancer
|
NCI
|
5R44CA119502-03
|
|
Commercialization of Image-Guided Liver Surgery
|
STEFANSIC, JAMES
|
PATHFINDER THERAPEUTICS
|
TN
|
$751,413
|
|
Liver Cancer
|
NCI
|
5R01CA112481-04
|
|
STEM CELLS AND HEPATOCARCINOGENESIS
|
SELL, STEWART
|
ORDWAY RESEARCH INSTITUTE, INC.
|
NY
|
$255,805
|
|
Liver Cancer
|
NCI
|
5R01CA080946-08
|
|
Selenoproteins as Targets for Cancer Prevention
|
GLADYSHEV, VADIM
|
UNIVERSITY OF NEBRASKA LINCOLN
|
NE
|
$79,589
|
|
Liver Cancer
|
NIDDK
|
5R21DK078100-02
|
|
Ribavirin Pharmacokinetics, Race and HCV Treatment
|
HOWELL, CHARLES
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$181,912
|
|
Liver Cancer
|
NIAID
|
7U01AI065871-04
|
|
Pathogenesis of Liver Fluke Induced Cancer in Thailand
|
BRINDLEY, PAUL
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$939,071
|
|
Liver Cancer
|
NIDDK
|
5K08DK065880-04
|
|
Targeting p27kip1 to Improve Hepatocyte Transplantation
|
OCHOA, ERIN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$126,630
|
|
Liver Cancer
|
NIDDK
|
5R01DK065772-05
|
|
Betaglycan as a modulator of TGF-beta signaling in hepatoma
|
WELLS, REBECCA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$235,648
|
|
Liver Cancer
|
NCI
|
1R21CA133649-01
|
|
Sphinx: a new cause of hepatic neoplasia
|
HOEBE, KASPER
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$195,750
|
|
Liver Cancer
|
NCI
|
5R01CA124414-02
|
|
BETA-CATENIN AS A THERAPEUTIC TARGET IN HEPATOCELLULAR CANCER
|
MONGA, SATDARSHAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$249,664
|
|
Liver Cancer
|
NIAID
|
5R21AI072180-02
|
|
Towards Developing type 1a HCV cell culture model
|
DASGUPTA, ASIM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$188,843
|
|
Liver Cancer
|
NIEHS
|
5R01ES005116-18
|
|
Biological Markers of Aflatoxin Exposure
|
SANTELLA, REGINA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$337,642
|
|
Liver Cancer
|
NCI
|
5R01CA122295-02
|
|
Androgen Receptor Roles in Liver Cancer Incidence and Progression
|
CHANG, CHAWNSHANG
|
UNIVERSITY OF ROCHESTER
|
NY
|
$292,600
|
|
Liver Cancer
|
NIGMS
|
5R01GM023750-33
|
|
Biologic Studies with Peroxisome Proliferators and PPARs
|
REDDY, JANARDAN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$480,009
|
|
Liver Cancer
|
NCI
|
5R01CA112192-02
|
|
Real-time Ultrasonic Monitoring of Tumor Ablation
|
VARGHESE, TOMY
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$246,955
|
|
Liver Cancer
|
NCI
|
5R01CA039225-23
|
|
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO
|
SIRICA, ALPHONSE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$288,953
|
|
Liver Cancer
|
NIAID
|
5R03AI069090-02
|
|
Role of mitochondrial core protein in Hepatitis C Virus pathogenesis
|
OTT, MELANIE
|
J. DAVID GLADSTONE INSTITUTES
|
CA
|
$95,648
|
|
Liver Cancer
|
NIAID
|
2R01AI040696-11A2
|
|
Regulation of HBV Replication by the Immune System
|
GUIDOTTI, LUCA
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$473,750
|
|
Liver Cancer
|
NIDA
|
5R01DA019841-09
|
|
Natural History of Hepatitis C Infection in HIV Disease
|
COTTON, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$866,282
|
|
Liver Cancer
|
NCI
|
5R01CA120206-03
|
|
Identification of Altered Glycan and Glycoproteins in Viral Induced Liver Cancer
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
PA
|
$317,565
|
|
Liver Cancer
|
NIEHS
|
5R01ES013534-04
|
|
Ultra-Low Dose Carcinogen Testing with the Trout Model
|
WILLIAMS, DAVID
|
OREGON STATE UNIVERSITY
|
OR
|
$434,603
|
|
Liver Cancer
|
NIDDK
|
1R01DK076918-01A2
|
|
Hepatocellular Carcinoma in Antitrypsin Deficiency
|
PERLMUTTER, DAVID
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$412,251
|
|
Liver Cancer
|
NCI
|
1R01CA125642-01A2
|
|
Urine Biomarker Discovery for Early Detection of Liver Cancer
|
SU, YING-HSIU
|
DREXEL UNIVERSITY
|
PA
|
$381,911
|
|
Liver Cancer
|
NCI
|
5R44CA069926-06
|
|
Saline Enhanced Radiofrequency Ablation for Liver Tumors
|
CURLEY, MICHAEL
|
E.P., LTD
|
MA
|
$945,936
|
|
Liver Cancer
|
NIDDK
|
2R01DK026506-26A2
|
|
Influence of Heme on Hepatic Cytochrome P450 Synthesis and Degradation
|
CORREIA, MARIA
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$483,407
|
|
Liver Cancer
|
NIDDK
|
5K08DK076598-02
|
|
The Pathogenesis of Steatosis in Hepatitis C Genotype 3 Infection
|
JHAVERI, RAVI
|
DUKE UNIVERSITY
|
NC
|
$124,308
|
|
Liver Cancer
|
NIDDK
|
5R01DK054921-10
|
|
The Cyclin D1/CDK4 Complex in Hepatocyte Proliferation
|
ALBRECHT, JEFFREY
|
MINNEAPOLIS MEDICAL RESEARCH FDN, INC.
|
MN
|
$262,026
|
|
Liver Cancer
|
NCI
|
1R01CA129414-01A1
|
|
Evaluation of novel FoxM1 inhibitors against liver cancer
|
GARTEL, ANDREI
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$325,775
|
|
Liver Cancer
|
NIDDK
|
5R01DK046546-15
|
|
Metabolic Regulation by the Nuclear Receptor CAR
|
MOORE, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$338,468
|
|
Liver Cancer
|
NIDDK
|
5R01DK074515-02
|
|
Role of HCV Sequence Variation in Pathology
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$318,528
|
|
Liver Cancer
|
NIGMS
|
1R01GM073937-01A2
|
|
Biodegradable Micelles for Liver-Targeted Gene Delivery
|
MAO, HAI-QUAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$270,514
|
|
Liver Cancer
|
NCCAM
|
2R01AT001576-06A1
|
|
ROLE OF SAMe IN LIVER FUNCTION AND INJURY
|
LU, SHELLY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$374,152
|
|
Liver Cancer
|
NIAAA
|
1R21AA016858-01A2
|
|
EFFECT OF ALCOHOL ON HEPATOCELLULAR CARCINOMA PROGRESSION IN VIVO
|
MCKILLOP, IAIN
|
CAROLINAS MEDICAL CENTER
|
NC
|
$161,595
|
|
Liver Cancer
|
NCI
|
1K22CA128866-01A1
|
|
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
|
BUCK, MARTINA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$148,770
|
|
Liver Cancer
|
NCI
|
5R03CA123604-02
|
|
Modulation of carcinogen-metabolizing enzyzmes by sulindac
|
CIOLINO, HENRY
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$75,000
|
|
Liver Cancer
|
NCI
|
1R21CA133976-01A2
|
|
Hepatitis B virus immune escape mutants
|
TONG, SHUPING
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$145,789
|
|
Liver Cancer
|
NCI
|
1R21CA122565-01A2
|
|
Correlative Genetic Markers in Childhood Hepatoblastoma
|
TOMLINSON, GAIL
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$251,763
|
|
Liver Cancer
|
NCI
|
5R01CA064239-13
|
|
Anti-angiogenic Barriers to Tumor Development
|
CRAWFORD, SUSAN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$260,253
|
|
Liver Cancer
|
NIDDK
|
5K01DK078532-02
|
|
Endocannabinoid Regulation of Cholangiocarcinoma Cell Growth
|
DEMORROW, SHARON
|
SCOTT AND WHITE MEMORIAL HOSPITAL
|
TX
|
$3,707
|
|
Liver Cancer
|
NCI
|
5K07CA118576-03
|
|
Comprehensive Electronic Support System for Treatment of Cancer-Related Symptoms
|
STEEL, JENNIFER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$131,585
|
|
Liver Cancer
|
NIEHS
|
5R01ES006376-16
|
|
Stress Signaling Pathways in Toxicity and Disease
|
KARIN, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$353,922
|
|
Liver Cancer
|
NCI
|
5K08CA111819-03
|
|
The Ron Receptor Tyrosine Kinase in Hepatic Tumorigenesis
|
LEONIS, MIKE
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$132,840
|
|
Liver Cancer
|
NIAAA
|
2R01AA009231-16A1
|
|
Alcohol-induced liver fibrosis:an in vitro model
|
ROJKIND, MARCOS
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$349,594
|
|
Liver Cancer
|
NCI
|
1R03CA133946-01
|
|
Advanced NMR/MRI Methods for Liver Cancer
|
TESIRAM, YASVIR
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$77,500
|
|
Liver Cancer
|
NCI
|
5U01CA084951-10
|
|
Early Detection of Liver Cancer
|
BLOCK, TIMOTHY
|
DREXEL UNIVERSITY
|
PA
|
$424,009
|
|
Liver Cancer
|
NIEHS
|
5R01ES015447-03
|
|
Mechanisms of Resistance of Aquatic Vertebrate Populations to Mixtures
|
WIRGIN, ISAAC
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$191,151
|
|
Liver Cancer
|
NIEHS
|
5R01ES014641-03
|
|
Lipid peroxidation product induced DNA damage in the p53 gene and liver cancer
|
TANG, ERIC MOON-SHONG
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$361,563
|
|
Liver Cancer
|
NIEHS
|
5R01ES014662-02
|
|
Serum Organochlorine Levels and Primary Liver Cancer: A Nested Case-Control Study
|
ENGEL, LAWRENCE
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$763,744
|
|
Liver Cancer
|
NIDDK
|
5R01DK064670-04
|
|
Preparative irradiation for hepatocyte transplantation
|
GUHA, CHANDAN
|
YESHIVA UNIVERSITY
|
NY
|
$362,489
|
|
Liver Cancer
|
NCI
|
5R01CA120372-03
|
|
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
|
WOO, SAVIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$595,625
|
|
Liver Cancer
|
NIEHS
|
5R21ES015954-02
|
|
Activating liver carcinogens in yeast by expressing CYP450 polymorphisms
|
FASULLO, MICHAEL
|
ORDWAY RESEARCH INSTITUTE, INC.
|
NY
|
$217,438
|
|
Liver Cancer
|
NCI
|
5R01CA112215-03
|
|
Chip Based Diagnosis of Problematic Liver Tumors
|
YEATMAN, TIMOTHY
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$417,714
|
|
Liver Cancer
|
NIDDK
|
5R01DK074419-03
|
|
Pathophysiological Interpretations of Dynamic PET/CT of Molecular Liver Biology
|
KEIDING, SUSANNE
|
AARHUS UNIVERSITY HOSPITAL
|
DENMAR
|
$159,274
|
|
Liver Cancer
|
NCI
|
1R43CA133993-01
|
|
Immune Response Modification for Treatment of Hepatocellular Carcinoma
|
FAIRMAN, JEFF
|
JUVARIS BIOTHERAPEUTICS, INC.
|
CA
|
$255,467
|
|
Liver Cancer
|
NIDDK
|
5R01DK076986-02
|
|
Integrative genomic analysis in hepatocellular carcinoma
|
LLOVET, JOSEP
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$258,082
|
|
Liver Cancer
|
NCI
|
5R01CA118761-02
|
|
p53 and pathways of apoptosis
|
GEORGE, DONNA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$299,250
|
|
Liver Cancer
|
NIDDK
|
5K24DK072036-04
|
|
Racial Disparities in Liver Diseases
|
HOWELL, CHARLES
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$194,250
|
|
Liver Cancer
|
NIDDK
|
5R01DK065982-05
|
|
Immune Response to Hepatitis C in Liver Transplantation
|
MOHANAKUMAR, THALACHALLOUR
|
WASHINGTON UNIVERSITY
|
MO
|
$334,102
|
|
Liver Cancer
|
NCI
|
5R01CA093840-06
|
|
Genesis of Liver Carcinomas with Oval Cell Traits
|
HIXSON, DOUGLAS
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$338,649
|
|
Liver Cancer
|
NCRR
|
5R21RR024229-02
|
|
New mouse model of hepatitis B virus-associated hepatocellular carcinoma
|
YEN, TIEN-SZE
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$193,060
|
|
Liver Cancer
|
NIDDK
|
5R01DK066840-05
|
|
Novel markers for HCV-related HCC
|
BERETTA, LAURA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$345,537
|
|
Liver Cancer
|
NIEHS
|
5R44ES012618-04
|
|
Predictive Genes Sets For Chemically-Induced Liver Cancer
|
NAUGHTON, BRIAN
|
REGENEMED, INC.
|
CA
|
$650,000
|
|
Liver Cancer
|
NIAID
|
1R13AI078719-01
|
|
2008 International Meeting: The Molecular Biology of Hepatitis B Viruses
|
WIELAND, STEFAN
|
HEPATITIS B FOUNDATION
|
PA
|
$15,000
|
|
Liver Cancer
|
NIDDK
|
1F30DK083235-01
|
|
Targeting the WntBeta-catenin Pathway in Liver Cancer
|
THOMPSON, MICHAEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$45,972
|
|
Liver Cancer
|
NCI
|
5R01CA123544-02
|
|
Biomarker for Hepatocellular Carcinoma
|
WANDS, JACK
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$237,762
|
|
Liver Cancer
|
NCI
|
5K07CA106458-04
|
|
Molecular Epidemiology of Chronic Liver Diseases
|
HASSAN, MANAL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$118,806
|
|
Liver Cancer
|
NIAID
|
5R01AI070827-03
|
|
High Throughput in vitro Hepatitis C Virus Screening
|
UPRICHARD, SUSAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$231,928
|
|
Liver Cancer
|
NCI
|
5R21CA122327-02
|
|
Aldose Reductase-Like-1, a Novel Hepatocellular Carcinoma Drug Resistant Protein
|
CAO, DELIANG
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
IL
|
$173,400
|
|
Liver Cancer
|
NIAAA
|
5F31AA016865-02
|
|
Hepatitis B Virus X Protein and Alcohol Regulation of Mitochondria and Apoptosis
|
CLIPPINGER, AMY
|
DREXEL UNIVERSITY
|
PA
|
$29,172
|
|
Liver Cancer
|
NIDDK
|
5R01DK069370-04
|
|
Mechanisms of Survival Signaling in Biliary Epithelia
|
PATEL, TUSHAR
|
OHIO STATE UNIVERSITY
|
OH
|
$209,073
|
|
Liver Cancer
|
NIAID
|
5R03AI067440-03
|
|
Feasibility for non-Invasive screening for HCV related fibrosis
|
MOHAMED, MOSTAFA
|
NATL HEPATOLOGY/TROPICAL MED RES INST
|
EGYPT
|
$43,078
|
|
Liver Cancer
|
NCI
|
5R01CA129763-02
|
|
A Randomized Trial of Hep B Screening and Vaccination in High Risk Vietnamese
|
MA, GRACE
|
TEMPLE UNIVERSITY
|
PA
|
$479,743
|
|
Liver Cancer
|
NCI
|
5R01CA113602-02
|
|
IKKbeta:Bi-Functional Regulator of Hepatocyte Proliferation
|
LEFFERT, HYAM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$293,550
|
|
Liver Cancer
|
NCI
|
5K22CA111393-03
|
|
The Renin-Angiotensin System in Hepatitis and Hepatoma
|
MALUCCIO, MARY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$161,285
|
|
Liver Cancer
|
NIDDK
|
5R01DK074816-02
|
|
Albumin-AFP Gene Family Regulation in Fetal and Adult Liver
|
SPEAR, BRETT
|
UNIVERSITY OF KENTUCKY
|
KY
|
$294,319
|
|
Liver Cancer
|
NCI
|
5R01CA124377-02
|
|
An Integrated System for Image-Guided Radiofrequency Ablation of Liver Tumors
|
CLEARY, KEVIN
|
GEORGETOWN UNIVERSITY
|
DC
|
$303,883
|
|
Liver Cancer
|
NCI
|
5R01CA125487-02
|
|
Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$291,650
|
|
Liver Cancer
|
NIDDK
|
5K01DK079875-02
|
|
Cholangiocyte microRNAs Regulate Mcl-1 and Cell Death
|
MOTT, JUSTIN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$121,499
|
|
Liver Cancer
|
NIDDK
|
5K01DK077137-02
|
|
The role of adiponectin in hepatocelluar carcinoma
|
SAXENA, NEERAJ
|
EMORY UNIVERSITY
|
GA
|
$125,245
|
|
Liver Cancer
|
NIDDK
|
5U01DK062467-07
|
|
Adult Live Donor Liver Transplant-A Comparative Analysis
|
ABECASSIS, MICHAEL
|
NORTHWESTERN UNIVERSITY
|
IL
|
$465,991
|
|
Liver Cancer
|
NIDDK
|
5R21DK079293-02
|
|
Transgenic mouse models of hepatitis C virus replication
|
LUO, GUANGXIANG
|
UNIVERSITY OF KENTUCKY
|
KY
|
$179,463
|
|
Liver Cancer
|
NCI
|
5R01CA074131-12
|
|
PATHOGENESIS OF HEPATOCELLULAR CARCINOMA
|
FAUSTO, NELSON
|
UNIVERSITY OF WASHINGTON
|
WA
|
$280,617
|
|
Liver Cancer
|
NCI
|
5R01CA113560-02
|
|
Carcinogen Exposure and Adult Cancer Risk
|
MCQUEEN, CHARLENE
|
AUBURN UNIVERSITY AT AUBURN
|
AL
|
$277,400
|
|
Liver Cancer
|
NCI
|
5R01CA122499-02
|
|
Oxidative Stress and Hepatocellular Carcinoma
|
HUANG, TING-TING
|
PALO ALTO INSTITUTE FOR RES & EDU, INC.
|
CA
|
$266,000
|
|
Liver Cancer
|
NCI
|
5F31CA130116-02
|
|
Determining the Progenitor-Like Capacity of Liver Cancer Cells in vivo.
|
PAULK, NICOLE
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$38,721
|
|
Liver Cancer
|
NCI
|
5R01CA127228-02
|
|
Mechanisms of PDGF-C Induced Hepatocellular Carcinogenesis
|
CAMPBELL, JEAN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$296,400
|
|
Liver Cancer
|
NIDDK
|
5F32DK081193-02
|
|
Characterization of the HCV p7 Protein
|
JONES, CHRISTOPHER
|
ROCKEFELLER UNIVERSITY
|
NY
|
$52,898
|
|
Liver Cancer
|
NCI
|
5R01CA035373-26
|
|
HGF in Liver Development, Regeneration and Neoplasia
|
MICHALOPOULOS, GEORGE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$329,101
|
|
Liver Cancer
|
NIAAA
|
5R01AA008169-19
|
|
HCV in Alcoholics
|
WANDS, JACK
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$323,323
|
|
Liver Cancer
|
NIBIB
|
5F31EB007170-02
|
|
MR-guided capacitive micromachined ultrasonic transducer for liver tumor ablation
|
WONG, SERENA
|
STANFORD UNIVERSITY
|
CA
|
$34,572
|
|
Liver Cancer
|
NIDDK
|
1R01DK081417-01
|
|
The Role of Hippo Pathway in Liver Regeneration
|
ANDERS, ROBERT
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$348,500
|
|
Liver Cancer
|
NIAID
|
1R01AI079031-01
|
|
Discovery of potent human antibodies for prevention of (recurrent) HCV infection
|
LAW, MANSUN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$473,750
|
|
Liver Cancer
|
NCI
|
1R01CA134719-01
|
|
Transcatheter Intra-arterial Perfusion MRI Monitoring of Liver Tumor Embolization
|
LARSON, ANDREW
|
NORTHWESTERN UNIVERSITY
|
IL
|
$302,637
|
|
Liver Cancer
|
NIAID
|
1K08AI079406-01
|
|
Novel antviral targets in Hepatitis C virus NS4B protein
|
EINAV, SHIRIT
|
STANFORD UNIVERSITY
|
CA
|
$130,599
|
|
Liver Cancer
|
NCI
|
1R21CA135519-01
|
|
Radiofrequency Tumor Ablation at Low Frequencies
|
HAEMMERICH, DIETER
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$165,938
|
|
Liver Cancer
|
NIDDK
|
1K99DK082080-01
|
|
Role of p53 and the p53-inducible Sestrin1 and 2 genes in hepatocarcinogenesis
|
BUDANOV, ANDREI
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$78,214
|
|
Liver Cancer
|
NIDDK
|
1K01DK081736-01
|
|
Genetic Epidemiology of HCV-related Liver Disease
|
WHITE, DONNA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$157,946
|
|
Liver Cancer
|
NIDDK
|
1R01DK077776-01A2
|
|
cPLA2alpha, COX-2 and TGF-beta in Liver Cancer
|
WU, TONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$321,938
|
|
Liver Cancer
|
NIEHS
|
2P01ES006052-15A1
|
0005
|
RESEARCH PROJECT 1: Chemical and Viral Biomarkers of Exposure and Risk (Groopman)
|
GROOPMAN, JOHN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$409,002
|
|
Liver Cancer
|
NCI
|
2R15CA108519-02
|
|
Amino Acid Transporters ASCT2 and LAT1 in Human Hepatocellular Cancer Growth
|
BODE, BARRIE
|
SAINT LOUIS UNIVERSITY
|
MO
|
$221,250
|
|
Liver Cancer
|
NCI
|
1R01CA131133-01A1
|
|
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma
|
ROBEK, MICHAEL
|
YALE UNIVERSITY
|
CT
|
$274,730
|
|
Liver Cancer
|
NIAID
|
1R01AI076535-01A1
|
|
Combination therapies for chronic HBV, liver disease and cancer
|
FEITELSON, MARK
|
TEMPLE UNIVERSITY
|
PA
|
$366,600
|
|
Liver Cancer
|
NCI
|
2R01CA100070-06A1
|
|
Regulation of cell growth by RNA binding proteins
|
TIMCHENKO, NIKOLAI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$266,844
|
|
Liver Cancer
|
NHLBI
|
2R37HL034557-20
|
|
Metabolism in the Heart by NMR
|
SHERRY, A. DEAN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$392,500
|
|
Liver Cancer
|
NCI
|
1R01CA126809-01A2
|
|
Functional MRI Monitoring of Hepatic Chemoembolization
|
OMARY, REED
|
NORTHWESTERN UNIVERSITY
|
IL
|
$313,325
|
|
Liver Cancer
|
NCI
|
1R01CA127481-01A2
|
|
Hepatocarcinogenesis Secondary to Hepatitis C
|
DASH, SRIKANTA
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$293,416
|
|
Liver Cancer
|
NCI
|
1R21CA133266-01A1
|
|
Development of 3D Differentiated Hepatocyte Culture Systems for the Study of HCC
|
UPRICHARD, SUSAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$200,550
|
|
Liver Cancer
|
NCCAM
|
1K01AT003448-01A2
|
|
Preclinical Studies of CAM Botanicals and Iron Overload
|
MESSNER, DONALD
|
BASTYR UNIVERSITY
|
WA
|
$121,190
|
|
Liver Cancer
|
NCI
|
1R21CA131625-01A1
|
|
A flexible somatic and sporadic mouse model for liver cancers
|
CHEN, XIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$168,905
|
|
Liver Cancer
|
NCI
|
1R21CA130837-01A1
|
|
Peptide Biomarker Discovery by Mass Spectrometry for Early Detection of Liver Can
|
RESSOM, HABTOM
|
GEORGETOWN UNIVERSITY
|
DC
|
$172,688
|
|
Liver Cancer
|
NCI
|
2R01CA132640-08A1
|
|
Regulation and Function of Mammalian HSF4 in vivo
|
MIVECHI, NAHID
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
GA
|
$265,594
|
|
Liver Cancer
|
NCI
|
1P01CA130821-01A1
|
0002
|
Cross Regulation of TGFB/elf, B-catenin and Vitamin D Pathways in Gastrointestina
|
BYERS, STEPHEN
|
GEORGETOWN UNIVERSITY
|
DC
|
$160,322
|
|
Liver Cancer
|
NCI
|
1P01CA130821-01A1
|
0003
|
Cellular Interactions between TGF-B Pathway Members and TERT and c-Myc in Gastroi
|
MISHRA, BIBHUTI
|
GEORGETOWN UNIVERSITY
|
DC
|
$162,824
|
|
Liver Cancer
|
NCI
|
1P01CA130821-01A1
|
9002
|
Cell Culture and Tissue Morphology Core
|
HADDAD, BASSEM
|
GEORGETOWN UNIVERSITY
|
DC
|
$106,294
|
|
Liver Cancer
|
NCI
|
1R41CA133991-01A1
|
|
Multiplex Electroluminescent Assay for Detection of Hepatocellular Carcinoma
|
MATHEW, ANU
|
MESO SCALE DIAGNOSTICS, LLC
|
MD
|
$199,257
|
|
Liver Cancer
|
NCI
|
1R44CA134169-01A1
|
|
Precisely Shaped Acoustic Ablation of Tumors Under 3D Ultrasound Image Guidance
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
IL
|
$150,000
|
|
Liver Cancer
|
NCI
|
1F32CA136135-01
|
|
A Population-Based Analysis of Care and Outcomes for Hepatocellular Carcinoma
|
MASSARWEH, NADER
|
UNIVERSITY OF WASHINGTON
|
WA
|
$54,746
|
|
Liver Cancer
|
NCI
|
5F32CA111040-03X1
|
|
Modulation of Hepatic N-Myristoyltransferases by Dioxins
|
WORMKE, MARK
|
NATL RESEARCH CTR/ENVIRONMENT & HEALTH
|
GERM
|
$7,000
|
|
Liver Cancer
|
NIAID
|
1F32AI080093-01
|
|
Reconstitution of Poliovirus and HCV RNA Replication Complexes on Membranes
|
PTACEK, JENNIFER
|
STANFORD UNIVERSITY
|
CA
|
$44,846
|
|
Liver Cancer
|
NIDDK
|
1F30DK082151-01
|
|
Regulation of hepcidin and iron metabolism in liver disease
|
GOODNOUGH, JULIA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$30,622
|
|
Liver Cancer
|
NIAAA
|
1F31AA017811-01
|
|
Hepatitis B Virus X protein and Alcohol Regulation of Cell Cycle Progression
|
GEARHART, TRICIA
|
DREXEL UNIVERSITY
|
PA
|
$27,255
|
|
Liver Cancer
|
NCI
|
1F31CA136183-01
|
|
FoxM1 and Oncogenic Pathways in Hepatocellular Carcinoma
|
CARR, JANAI
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$45,972
|
|
Liver Cancer
|
NIAID
|
5U19AI066313-04
|
0002
|
Hepatitis C Virus- Induced Steatosis
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$160,781
|
|
Liver Cancer
|
NIAID
|
5U19AI066313-04
|
0003
|
Viral, T Cell, and Cytokine Determinants of Hepatic Stellate Cell Activation
|
SCHUPPAN, DETLEF
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$110,208
|
|
Liver Cancer
|
NCI
|
3R01CA100882-05S1
|
|
Molecular Pathogenesis of Hepatocellular Carcinoma
|
ROBERTS, LEWIS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$110,337
|
|
Liver Cancer
|
NCI
|
3R01CA100882-05S2
|
|
Molecular Pathogenesis of Hepatocellular Carcinoma
|
ROBERTS, LEWIS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$49,975
|
|
Liver Cancer
|
NCI
|
3R01CA100882-05S3
|
|
Molecular Pathogenesis of Hepatocellular Carcinoma
|
ROBERTS, LEWIS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$84,616
|
|
Liver Cancer
|
NIDDK
|
1U01DK082843-01
|
|
Optimal Long-term Outcome of Chronic Hepatitis B
|
KIM, W. RAY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$157,025
|
|
Liver Cancer
|
NIDDK
|
1U01DK082874-01
|
|
Durability of HBV DNA Suppression in Cirrhotics After Stopping Therapy
|
HEATHCOTE, E
|
UNIVERSITY HEALTH NETWORK
|
CANADA
|
$101,548
|
|
Liver Cancer
|
NIDDK
|
1U01DK082867-01
|
|
The North Carolina Hepatitis Beta Clinical Research Network
|
FRIED, MICHAEL
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$149,081
|
|
Liver Cancer
|
NIDDK
|
1U01DK082863-01
|
|
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
|
LOK, ANNA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$143,168
|
|
Liver Cancer
|
NIDDK
|
1U01DK082866-01
|
|
Immune regulation and co-stimulation in treatment outcome of chronic hepatitis B
|
CHANG, KYONG-MI
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$86,247
|
|
Liver Cancer
|
NIDDK
|
1U01DK082919-01
|
|
Harvard Hepatitis B Consortium
|
LAU, DARYL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$129,767
|
|
Liver Cancer
|
NIDDK
|
1U01DK082944-01
|
|
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection
|
TERRAULT, NORAH
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$149,154
|
|
Liver Cancer
|
NIDDK
|
1U01DK082916-01
|
|
Effect of HBV DNA Methylation and the Mutant 1762T/1764A on Viral Load and HCC
|
SCHWARZ, KATHLEEN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$91,495
|
|
Liver Cancer
|
NIDDK
|
1U01DK082927-01
|
|
HBV Research Network Database Protocol and Clinical Trial Study Proposals
|
HAN, STEVEN-HUY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$144,242
|
|
Liver Cancer
|
NIDDK
|
2R01DK066423-05A2
|
|
Determinants of Sinusoidal Endothelial Cell Phenotype.
|
DELEVE, LAURIE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$346,375
|
|
Liver Cancer
|
NIEHS
|
5P42ES010337-09
|
0010
|
Mouse Strain With Elevated Sensitivity to Chemical
|
KARIN, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$306,888
|
|
Liver Cancer
|
NIEHS
|
5P42ES013661-03
|
0001
|
Project 1: PCBs: Metabolism, Genotoxicity and Gene Expression In Vivo
|
ROBERTSON, LARRY
|
UNIVERSITY OF IOWA
|
IA
|
$459,019
|
|
Liver Cancer
|
NIEHS
|
5P42ES005948-16
|
0001
|
DNA Adducts as Biomarkers of Exposure and Effect - Biomedical
|
SWENBERG, JAMES
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$339,616
|
|
Liver Cancer
|
NCI
|
5P01CA022484-28
|
0006
|
GENETIC MODIFIERS OF MURINE HEPATOCARCINOGENESIS
|
DRINKWATER, NORMAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$261,087
|
|
Liver Cancer
|
NCI
|
5P01CA022484-28
|
0010
|
QUANTIFYING GENE EFFECTS ON HEPATIC CANCER IN VIVO
|
SANDGREN, ERIC
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$262,989
|
|
Liver Cancer
|
NCI
|
3D43TW000010-21S2
|
|
Training in HIV Associated Malignacies, Rakai, Uganda
|
BEYRER, CHRIS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$145,941
|
|
Liver Cancer
|
NCI
|
7R01CA127387-02
|
|
Role of the RB tumor suppressor in liver tumorigenesis
|
KNUDSEN, ERIK
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$320,761
|
|
Liver Cancer
|
NCI
|
3U54CA126513-02S1
|
|
The Role of Inflammation and Stroma in Digestive Cancer
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$29,953
|
|
Liver Cancer
|
NCI
|
3R01CA124488-02S1
|
|
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
|
RAYCHAUDHURI, PRADIP
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$35,757
|
|
Liver Cancer
|
NCI
|
5S06GM008012-38
|
0010
|
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma
|
ZHANG, JIANYING
|
UNIVERSITY OF TEXAS EL PASO
|
TX
|
$9,385
|
|
Liver Cancer
|
NIAID
|
5S06GM008012-38
|
0010
|
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma
|
ZHANG, JIANYING
|
UNIVERSITY OF TEXAS EL PASO
|
TX
|
$5,652
|
|
Liver Cancer
|
NIGMS
|
5S06GM008012-38
|
0010
|
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma
|
ZHANG, JIANYING
|
UNIVERSITY OF TEXAS EL PASO
|
TX
|
$79,153
|
|
Liver Cancer
|
NCI
|
5P01CA123328-02
|
0001
|
TRANSGENIC MICE AS A MODEL FOR HBV REPLICATION AND ONCOGENESIS
|
OU, J.-H. JAMES
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$293,727
|
|
Liver Cancer
|
NCI
|
5P01CA123328-02
|
0002
|
HEPATIC CARCINOGENESIS INDUCED BY HEPATITIS B VIRUS PreS2 MUTANT
|
YEN, TIEN-SZE
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$469,011
|
|
